To our valued customers,

We at ABF want you to know that we are committed to you. We are closely monitoring the pandemic, following guidance and advice from the World Health Organization (WHO) and local health organizations.

Press Release

Kiel and Hamburg, Germany, and Vienna, Austria, 06 March 2020 - LKF - Laboratorium für Klinische Forschung GmbH, a subsidiary of GBA Group Pharma, is honouring International Women's Day on 8 March 2020 by highlighting the company's female success factors.

"Every day is Women's Day at LKF," says Bärbel Wilke, co-founder and CEO of LKF, with 80 percent of its 150 employees being women. Many of the 120 female employees working in the three-storey laboratory are highly qualified specialists and scientists from the fields of chemistry, biology, molecular biology et al.

The “standstill” transition period begins as the Withdrawal Agreement clears the final hurdle.

Three-and-a-half years since the Brexit vote, the UK has left the EU – with a deal. There was no late drama as the European Parliament approved the Withdrawal Agreement by 621 votes to 49.

The UK now enters a “transition period.” Although the UK will have no MEPs, no Commissioner, and no seat at the EU Council; EU law will continue to apply in the UK. And that means companies can continue UK batch release testing and qualified person (QP) certification; marketing authorization (MA) holders and QPs, and QPPVs can continue to be based in the UK and access EU markets; manufacturing and distribution licences will continue to be recognized by the EU and vice versa, as will inspections; and UK-based firms can continue to apply for MAs via either the centralized or decentralized procedure (1) * published in the Medicine Maker on 11th of February 2020

Medikamente. Import, Export und Herstellung von Arzneimittelnin der EU stehen im Fokus von ABF Pharmaceutical Services.

Gerade rechtzeitig zum Brexit hat die 2004 in Wien gegründete ABF Pharmaceutical Services (GBA Group Pharma), der einzige internationale Komplettdienstleister für Import, Export und Herstellung von Medikamenten in klinischen Studien (Prüfware) in Österreich, ihre Kapazitäten am neuen Standort in Wien 23 mehr als verdoppelt. Und das nicht nur aufgrund der wachsenden Nachfrage der internationalen Pharma- und Biotech-Branche, sondern auch um der Rolle eines Brexit Safe Havens gerecht zu werden.

ABF, ein Komplettdienstleister für klinische Prüfware am Standort Wien, hat seine Kapazitäten deutlich erweitert. Der Brexit könnte für zusätzliches Wachstum sorgen.

Eine klinische Phase-III-Studie ist angelaufen: An mehreren klinischen Zentren wird ein Präparat mit einem neu entwickelten Wirkstoff an Patienten getestet, die zuvor dafür rekrutiert wurden. Die Teilnehmer …

veröffentlicht im Chemiereport | AustrianLifeSciences | 2020.1